» Articles » PMID: 32645275

Novel Advances in Biotransformation and Bioactivation Research-2019 Year in Review

Overview
Journal Drug Metab Rev
Publisher Informa Healthcare
Specialty Pharmacology
Date 2020 Jul 10
PMID 32645275
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Biotransformation is one of the main mechanisms used by the body to eliminate drugs. As drug molecules become more complicated, the involvement of drug metabolizing enzymes increases beyond those that are typically studied, such as the cytochrome P450 enzymes. In this review, we try to capture the many outstanding articles that were published in the past year in the field of biotransformation (see Table 1). We have divided the articles into two categories of (1) metabolites and drug metabolizing enzymes, and (2) bioactivation and safety.  This annual review is the fifth of its kind since 2016 (Baillie et al. 2016; Khojasteh et al. 2017, 2018, 2019). This effort in itself also continues to evolve. We have followed the same format we used in previous years in terms of the selection of articles and the authoring of each section. I am pleased of the continued support of Rietjens, Miller, Zhang, Driscoll and Mitra to this review. We would like to welcome Klarissa D. Jackson as a new author for this year's issue. We strive to maintain a balance of authors from academic and industry settings.  We would be pleased to hear your opinions of our commentary, and we extend an invitation to anyone who would like to contribute to a future edition of this review. Cyrus Khojasteh, on behalf of the authors.

Citing Articles

Bioactivation and reactivity research advances - 2021 year in review.

Jackson K, Argikar U, Cho S, Crouch R, Driscoll J, Heck C Drug Metab Rev. 2022; 54(3):246-281.

PMID: 35876116 PMC: 10282953. DOI: 10.1080/03602532.2022.2097254.


Biotransformation novel advances - 2021 year in review.

Khojasteh S, Argikar U, Cho S, Crouch R, Heck C, Johnson K Drug Metab Rev. 2022; 54(3):207-245.

PMID: 35815654 PMC: 10249656. DOI: 10.1080/03602532.2022.2097253.


Novel advances in biotransformation and bioactivation research - 2020 year in review.

Khojasteh S, Argikar U, Driscoll J, Heck C, King L, Jackson K Drug Metab Rev. 2021; 53(3):384-433.

PMID: 33910427 PMC: 8826528. DOI: 10.1080/03602532.2021.1916028.

References
1.
Khojasteh S, Rietjens I, Dalvie D, Miller G . Biotransformation and bioactivation reactions - 2016 literature highlights. Drug Metab Rev. 2017; 49(3):285-317. DOI: 10.1080/03602532.2017.1326498. View

2.
Shimizu M, Fukami T, Nakajima M, Yokoi T . Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. Drug Metab Dispos. 2014; 42(7):1103-9. DOI: 10.1124/dmd.114.056994. View

3.
Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B . Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. J Pharmacol Exp Ther. 2017; 363(2):240-252. DOI: 10.1124/jpet.117.242909. View

4.
Li X, Hayes M, Gronberg G, Berggren K, Castagnoli Jr N, Weidolf L . Discovery of a Novel Microsomal Epoxide Hydrolase-Catalyzed Hydration of a Spiro Oxetane. Drug Metab Dispos. 2016; 44(8):1341-8. DOI: 10.1124/dmd.116.071142. View

5.
Czerwinski M, McLemore T, Philpot R, Nhamburo P, Korzekwa K, Gelboin H . Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: evidence for species-specific metabolism. Cancer Res. 1991; 51(17):4636-8. View